R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
NTX-101
  • HOME
  • R&D
  • NTX-101

Eye Drops for Ischemic Optic Neuropathy

NTX-101 is the first-in-class eye drops treatment that inhibit the activity of the well-established target 11β-HSD1 by simultaneously lowering intraocular pressure and protecting the optic nerve.
NTX-101 is being developed as a therapy for ischemic optic neuropathy, such as NAION (non-arterial anterior ischemic optic neuropathy), AAC (acute anterior angle occlusion), and glaucoma.

Clinical trial status

Pipeline Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
NTX-101 NAION, AAC, Glaucoma
KR - Single Agent (Inje Univ.)